Anthony Conway, Ph.D.

Associate Director of Cell Therapy, Sangamo Therapeutics

Anthony Conway has led several genome editing research programs at Sangamo over the past 7 years and has been working in the gene and cell therapy field for over 12 years. His group is currently primarily focused on developing genome edited regulatory T cell therapies for solid organ transplant tolerization and autoimmune disorders. His group is also developing non-viral delivery technologies for both in vivo and ex vivo genome editing therapeutic strategies.